GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Gross-Profit-to-Asset %

Rize Oncology (XCNQ:RIZE) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Rize Oncology's annualized Gross Profit for the quarter that ended in Dec. 2024 was C$0.00 Mil. Rize Oncology's average Total Assets over the quarter that ended in Dec. 2024 was C$1.54 Mil. Therefore, Rize Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.


Rize Oncology Gross-Profit-to-Asset % Historical Data

The historical data trend for Rize Oncology's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Gross-Profit-to-Asset % Chart

Rize Oncology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
- - - - -

Rize Oncology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rize Oncology's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Rize Oncology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rize Oncology's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rize Oncology's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Rize Oncology's Gross-Profit-to-Asset % falls into.


;
;

Rize Oncology Gross-Profit-to-Asset % Calculation

Rize Oncology's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0/( (1.893+1.698)/ 2 )
=0/1.7955
=0.00 %

Rize Oncology's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (1.376+1.698)/ 2 )
=0/1.537
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Rize Oncology Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rize Oncology Business Description

Traded in Other Exchanges
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1
Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.
Executives
William James Garner 10% Security Holder, Director

Rize Oncology Headlines

No Headlines